Addendum
Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Report documents
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Dossier assessment
Adults with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Now hint of lesser benefit in comparison with continuation of ongoing therapy for pretreated adults with HIV-1 infection without indication for a treatment switch (before: added benefit not proven)
Additional information
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.
Project details
- Project no.
- A19-103
- Commission
- Commission awarded on 09.12.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Status: Commission completed
-
Dossier assessment
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed